cyc 202 has been researched along with brassinolide in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (brassinolide) | Trials (brassinolide) | Recent Studies (post-2010) (brassinolide) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 598 | 0 | 306 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arısan, ED; Coker Gurkan, A; Kara, M; Obakan Yerlikaya, P; Okumus, OO; Ozbey, U; Palavan Unsal, N; Yenigun, T | 1 |
1 other study(ies) available for cyc 202 and brassinolide
| Article | Year |
|---|---|
Epibrassinolide prevents tau hyperphosphorylation via GSK3β inhibition in vitro and improves Caenorhabditis elegans lifespan and motor deficits in combination with roscovitine.
Topics: Animals; Brassinosteroids; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Drug Therapy, Combination; Glycogen Synthase Kinase 3 beta; Longevity; Motor Disorders; Neuroprotective Agents; Phosphorylation; Plant Growth Regulators; Protein Kinase Inhibitors; Roscovitine; Steroids, Heterocyclic; tau Proteins | 2021 |